|
US3906092A
(en)
|
1971-11-26 |
1975-09-16 |
Merck & Co Inc |
Stimulation of antibody response
|
|
US6133433A
(en)
|
1984-07-27 |
2000-10-17 |
City Of Hope |
Method for detection and prevention of human cytomegalovirus infection
|
|
US6242567B1
(en)
|
1984-07-27 |
2001-06-05 |
City Of Hope |
Method for detection and prevention of human cytomegalovirus infection
|
|
US6162620A
(en)
|
1986-03-07 |
2000-12-19 |
Cogent Limited |
Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
|
|
CA1335429C
(en)
*
|
1986-03-07 |
1995-05-02 |
Geoffrey L. Smith |
Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
|
|
US6207161B1
(en)
|
1986-07-16 |
2001-03-27 |
City Of Hope |
Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
|
|
ATE240401T1
(de)
|
1989-03-21 |
2003-05-15 |
Vical Inc |
Expression von exogenen polynukleotidsequenzen in wirbeltieren
|
|
CA2128616A1
(en)
|
1992-01-23 |
1993-08-05 |
Gary H. Rhodes |
Ex vivo gene transfer
|
|
IL112820A0
(en)
|
1994-03-07 |
1995-05-26 |
Merck & Co Inc |
Coordinate in vivo gene expression
|
|
WO1995026204A1
(en)
|
1994-03-25 |
1995-10-05 |
Isis Pharmaceuticals, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
WO1995033835A1
(en)
|
1994-06-02 |
1995-12-14 |
Chiron Corporation |
Nucleic acid immunization using a virus-based infection/transfection system
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
WO1997040165A1
(en)
|
1996-04-23 |
1997-10-30 |
The Wistar Institute Of Anatomy And Biology |
Novel human cytomegalovirus dna constructs and uses therefor
|
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
|
US6074645A
(en)
|
1996-11-12 |
2000-06-13 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
|
US6156317A
(en)
|
1996-11-12 |
2000-12-05 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
|
US6562345B1
(en)
|
1996-11-12 |
2003-05-13 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
|
US20030073640A1
(en)
|
1997-07-23 |
2003-04-17 |
Ribozyme Pharmaceuticals, Inc. |
Novel compositions for the delivery of negatively charged molecules
|
|
CA2305785A1
(en)
|
1997-10-07 |
1999-04-15 |
University Of Maryland Biotechnology Institute |
Method for introducing and expressing rna in animal cells
|
|
JP2002500010A
(ja)
|
1997-12-23 |
2002-01-08 |
カイロン コーポレイション |
ヒト遺伝子および遺伝子発現産物ｉ
|
|
DE19910044A1
(de)
|
1999-03-08 |
2000-09-14 |
Bodo Plachter |
Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
|
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
|
ATE289630T1
(de)
|
1999-09-09 |
2005-03-15 |
Curevac Gmbh |
Transfer von mrnas unter verwendung von polykationischen verbindungen
|
|
AU7725500A
(en)
|
1999-09-30 |
2001-04-30 |
National Jewish Medical And Research Center |
Method for inhibition of pathogenic microorganisms
|
|
US6632435B1
(en)
|
1999-10-20 |
2003-10-14 |
City Of Hope |
CTL epitope analogs
|
|
US7060291B1
(en)
|
1999-11-24 |
2006-06-13 |
Transave, Inc. |
Modular targeted liposomal delivery system
|
|
US6835383B2
(en)
|
2000-03-23 |
2004-12-28 |
City Of Hope |
Protein kinase deficient, immunologically active CMVpp65 mutants
|
|
US6998115B2
(en)
|
2000-10-10 |
2006-02-14 |
Massachusetts Institute Of Technology |
Biodegradable poly(β-amino esters) and uses thereof
|
|
JP4099058B2
(ja)
|
2000-10-20 |
2008-06-11 |
シティ・オブ・ホープ |
ヒトサイトメガロウィルスｐｐ１５０の免疫反応性ペプチドｃｔｌエピトープ
|
|
US7204990B1
(en)
|
2000-11-28 |
2007-04-17 |
Medimmune Vaccines, Inc. |
Attenuation of cytomegalovirus virulence
|
|
US7708915B2
(en)
|
2004-05-06 |
2010-05-04 |
Castor Trevor P |
Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
|
|
US7514099B2
(en)
|
2005-02-14 |
2009-04-07 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
EP2842964A1
(de)
|
2001-06-05 |
2015-03-04 |
Curevac GmbH |
Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
|
|
WO2003011443A2
(en)
|
2001-07-27 |
2003-02-13 |
President And Fellows Of Harvard College |
Laminar mixing apparatus and methods
|
|
US20060051424A1
(en)
|
2001-10-03 |
2006-03-09 |
Johns Hopkins University |
Compositions of oral gene therapy and methods of using same
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
AU2003235707A1
(en)
*
|
2002-01-18 |
2003-07-30 |
Curevac Gmbh |
Immunogenic preparations and vaccines on the basis of mrna
|
|
US20050222064A1
(en)
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
|
WO2003092665A2
(en)
|
2002-05-02 |
2003-11-13 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
PT2311848E
(pt)
|
2002-12-23 |
2013-10-03 |
Vical Inc |
Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
|
|
US20040228842A1
(en)
*
|
2003-02-27 |
2004-11-18 |
Shan Lu |
Compositions and methods for cytomegalovirus treatment
|
|
WO2004093905A1
(en)
|
2003-04-16 |
2004-11-04 |
City Of Hope |
Human cytomegalovirus antigens expressed in mva and methods of use
|
|
EP1636385A4
(en)
|
2003-06-24 |
2010-06-02 |
Mirus Bio Corp |
INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS
|
|
PT1651666E
(pt)
|
2003-07-11 |
2009-08-28 |
Alphavax Inc |
Vacinas de citomegalovírus à base de alfavírus
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
WO2005034979A2
(en)
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
WO2005072710A2
(en)
|
2004-01-28 |
2005-08-11 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
|
MXPA06011871A
(es)
|
2004-04-15 |
2007-10-08 |
Chiasma Inc |
Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
|
|
DE102004035227A1
(de)
|
2004-07-21 |
2006-02-16 |
Curevac Gmbh |
mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
US7976845B2
(en)
*
|
2004-11-29 |
2011-07-12 |
The Council Of The Queensland Institute Of Medical Research |
Human cytomegalovirus immunotherapy
|
|
EP1856179B1
(en)
|
2004-12-10 |
2013-05-15 |
Kala Pharmaceuticals, Inc. |
Functionalized poly (ether-anhydride) block copolymers
|
|
WO2006071903A2
(en)
|
2004-12-28 |
2006-07-06 |
Ptc Therapeutics, Inc. |
Cell based methods and systems for the identification of rna regulatory sequences and compounds that modulate their functions
|
|
US8192718B1
(en)
|
2005-01-04 |
2012-06-05 |
Gp Medical, Inc. |
Pharmaceutical composition of nanoparticles
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
EP1910825B1
(en)
|
2005-03-11 |
2012-08-08 |
Firalis SAS |
Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds
|
|
WO2006107903A2
(en)
|
2005-04-01 |
2006-10-12 |
Intezyne Technologies, Incorporated |
Polymeric micelles for drug delivery
|
|
EP1885403B1
(en)
|
2005-04-12 |
2013-05-08 |
Nektar Therapeutics |
Poly(ethyleneglycol) conjugates of Lysostaphin
|
|
EP1912679A4
(en)
*
|
2005-06-15 |
2009-07-29 |
Massachusetts Inst Technology |
AMINOUS LIPIDS AND ITS USES
|
|
HUE025208T2
(en)
|
2005-06-16 |
2016-03-29 |
Nektar Therapeutics |
Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
|
|
RS63964B1
(sr)
|
2005-08-23 |
2023-03-31 |
Univ Pennsylvania |
Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
|
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
|
EP1986695B1
(en)
|
2006-02-21 |
2015-06-03 |
Nektar Therapeutics |
Segmented degradable polymers and conjugates made therefrom
|
|
CA2652280C
(en)
|
2006-05-15 |
2014-01-28 |
Massachusetts Institute Of Technology |
Polymers for functional particles
|
|
EP3031469B1
(en)
|
2006-06-07 |
2023-08-23 |
The Trustees Of Princeton University |
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
|
|
EP2046954A2
(en)
|
2006-07-31 |
2009-04-15 |
Curevac GmbH |
NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
|
|
DE602007012559D1
(de)
|
2006-09-08 |
2011-03-31 |
Univ Johns Hopkins |
H die schleimhaut
|
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
|
ES2447516T3
(es)
|
2006-12-21 |
2014-03-12 |
Stryker Corporation |
Formulaciones de liberación sostenida que comprenden cristales BMP-7
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
JP2010519203A
(ja)
|
2007-02-16 |
2010-06-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
生物活性分子の活性を強化するための組成物及び方法
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
JP5410434B2
(ja)
|
2007-09-28 |
2014-02-05 |
バインド セラピューティックス インコーポレイテッド |
ナノ粒子を用いた癌細胞の標的化
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
|
CA2710534C
(en)
|
2008-01-31 |
2018-09-04 |
Curevac Gmbh |
Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
ES2765240T3
(es)
|
2008-06-16 |
2020-06-08 |
Pfizer |
Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
|
|
PL2285350T3
(pl)
|
2008-06-16 |
2018-03-30 |
Pfizer Inc. |
Sposoby otrzymywania funkcjonalizowanych kopolimerów dwublokowych stanowiących środki kierujące do stosowania przy wytwarzaniu nanocząstek terapeutycznych
|
|
WO2010005726A2
(en)
|
2008-06-16 |
2010-01-14 |
Bind Biosciences Inc. |
Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
|
|
EA020753B1
(ru)
|
2008-06-16 |
2015-01-30 |
Бинд Терапьютикс, Инк. |
Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
|
|
CA2728739C
(en)
|
2008-06-20 |
2017-07-11 |
Duke University |
Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
|
|
EP2326331A4
(en)
|
2008-08-18 |
2013-05-15 |
Merck Sharp & Dohme |
NEW LIPID NANOPARTICLES AND NEW COMPONENTS FOR THE RELEASE OF NUCLEIC ACIDS
|
|
WO2010030763A2
(en)
|
2008-09-10 |
2010-03-18 |
Bind Biosciences, Inc. |
High throughput fabrication of nanoparticles
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
AU2015210364B2
(en)
|
2008-10-09 |
2017-03-09 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
JP5777519B2
(ja)
|
2008-10-09 |
2015-09-09 |
テクミラ ファーマシューティカルズ コーポレイション |
改良されたアミノ脂質および核酸の送達方法
|
|
CA2739046A1
(en)
|
2008-10-16 |
2010-04-22 |
Marina Biotech, Inc. |
Process and compositions for liposomal and effective delivery of nucleic acids
|
|
WO2010053572A2
(en)
|
2008-11-07 |
2010-05-14 |
Massachusetts Institute Of Technology |
Aminoalcohol lipidoids and uses thereof
|
|
DK2355851T3
(en)
|
2008-11-10 |
2018-06-25 |
Arbutus Biopharma Corp |
Newly known lipids and compositions for release of therapeutic agents
|
|
CA2780482A1
(en)
|
2008-11-17 |
2010-05-10 |
Anil K. Sood |
Hdl particles for delivery of nucleic acids
|
|
ES2776126T3
(es)
|
2008-12-15 |
2020-07-29 |
Pfizer |
Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
|
|
WO2010080724A1
(en)
|
2009-01-12 |
2010-07-15 |
Merck Sharp & Dohme Corp. |
Novel lipid nanoparticles and novel components for delivery of nucleic acids
|
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
|
JP5622254B2
(ja)
|
2009-03-31 |
2014-11-12 |
国立大学法人東京大学 |
二本鎖リボ核酸ポリイオンコンプレックス
|
|
WO2010127159A2
(en)
|
2009-04-30 |
2010-11-04 |
Intezyne Technologies, Incorporated |
Polymeric micelles for polynucleotide encapsulation
|
|
US8580276B2
(en)
|
2009-06-05 |
2013-11-12 |
City Of Hope |
Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
|
|
US9732337B2
(en)
|
2009-06-16 |
2017-08-15 |
The United Stated of America, as represented by the Secretary, Department of Health & Human Services |
RNA nanoparticles and nanotubes
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
|
WO2011005799A2
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
EP2467357B1
(en)
|
2009-08-20 |
2016-03-30 |
Sirna Therapeutics, Inc. |
Novel cationic lipids with various head groups for oligonucleotide delivery
|
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
|
WO2011043913A2
(en)
|
2009-10-08 |
2011-04-14 |
Merck Sharp & Dohme Corp. |
Novel cationic lipids with short lipid chains for oligonucleotide delivery
|
|
EP2496700B1
(en)
|
2009-11-04 |
2017-03-01 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
|
ME03091B
(me)
|
2009-12-01 |
2019-01-20 |
Translate Bio Inc |
Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
JP5898627B2
(ja)
|
2009-12-15 |
2016-04-06 |
バインド セラピューティックス インコーポレイテッド |
エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
|
|
WO2011084513A2
(en)
|
2009-12-15 |
2011-07-14 |
Bind Biosciences, Inc. |
Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
|
|
JP6175237B2
(ja)
|
2009-12-15 |
2017-08-02 |
ファイザー・インク |
コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法
|
|
EP2525781A1
(en)
|
2010-01-22 |
2012-11-28 |
Schering Corporation |
Novel cationic lipids for oligonucleotide delivery
|
|
JP5988435B2
(ja)
|
2010-01-24 |
2016-09-07 |
ノバルティス アーゲー |
放射線照射された生分解性微粒子
|
|
US8207290B2
(en)
|
2010-03-26 |
2012-06-26 |
Cerulean Pharma Inc. |
Methods and systems for generating nanoparticles
|
|
EP2556150B1
(en)
|
2010-04-06 |
2016-08-24 |
Vakzine Projekt Management GmbH |
Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof
|
|
US20130037977A1
(en)
|
2010-04-08 |
2013-02-14 |
Paul A. Burke |
Preparation of Lipid Nanoparticles
|
|
US20110262491A1
(en)
|
2010-04-12 |
2011-10-27 |
Selecta Biosciences, Inc. |
Emulsions and methods of making nanocarriers
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
US9254327B2
(en)
|
2010-05-10 |
2016-02-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
EP2569276B1
(en)
|
2010-05-12 |
2021-02-24 |
Arbutus Biopharma Corporation |
Novel cationic lipids and methods of use thereof
|
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
|
JP2013531634A
(ja)
|
2010-05-24 |
2013-08-08 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
|
|
DK2575767T3
(en)
|
2010-06-04 |
2017-03-13 |
Sirna Therapeutics Inc |
HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
|
|
WO2011163483A2
(en)
|
2010-06-25 |
2011-12-29 |
Massachusetts Institute Of Technology |
Polymers for biomaterials and therapeutics
|
|
DK2590676T3
(en)
*
|
2010-07-06 |
2016-10-24 |
Glaxosmithkline Biologicals Sa |
Virionlignende feed particles to self-replicating RNA molecules
|
|
JP5940064B2
(ja)
*
|
2010-07-06 |
2016-06-29 |
ノバルティス アーゲー |
低用量のｒｎａを用いた大型哺乳動物の免疫化
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
JP5948327B2
(ja)
|
2010-07-30 |
2016-07-06 |
キュアヴァック アーゲー |
トランスフェクションおよび免疫刺激のためのジスルフィド架橋されたカチオン性成分との核酸の複合体形成
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
AU2011291522A1
(en)
*
|
2010-08-20 |
2013-01-24 |
Selecta Biosciences, Inc. |
Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza A virus M2E
|
|
EA201390145A1
(ru)
|
2010-08-20 |
2013-11-29 |
Серулин Фарма Инк. |
Конъюгаты, частицы, композиции и связанные с ними способы
|
|
SMT202200311T1
(it)
|
2010-08-31 |
2022-09-14 |
Glaxosmithkline Biologicals Sa |
Liposomi pegilati per somministrare rna codificante un immunogene
|
|
HRP20221048T1
(hr)
|
2010-08-31 |
2022-11-11 |
Glaxosmithkline Biologicals Sa |
Mali liposomi za isporuku rna koja kodira imunogen
|
|
EP2614072A4
(en)
|
2010-09-09 |
2014-03-19 |
Univ Virginia Commonwealth |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
WO2012039979A2
(en)
|
2010-09-10 |
2012-03-29 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
WO2012040184A2
(en)
|
2010-09-20 |
2012-03-29 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
|
CA2811430A1
(en)
|
2010-09-30 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
DK4108671T3
(da)
|
2010-10-01 |
2025-01-06 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
|
|
EP3520813B1
(en)
*
|
2010-10-11 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Antigen delivery platforms
|
|
EP3485913A1
(en)
|
2010-10-21 |
2019-05-22 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
EP2629760A4
(en)
|
2010-10-22 |
2014-04-02 |
Bind Therapeutics Inc |
THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT
|
|
WO2012061703A1
(en)
|
2010-11-05 |
2012-05-10 |
The Johns Hopkins University |
Compositions and methods relating to reduced mucoadhesion
|
|
EP2635265B1
(en)
|
2010-11-05 |
2018-04-04 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
JP5902197B2
(ja)
|
2011-01-11 |
2016-04-13 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
|
|
US20120189700A1
(en)
|
2011-01-19 |
2012-07-26 |
Zoraida Aguilar |
Nanoparticle Based Immunological Stimulation
|
|
WO2012106377A2
(en)
|
2011-01-31 |
2012-08-09 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
|
|
WO2012109121A1
(en)
|
2011-02-07 |
2012-08-16 |
Purdue Research Foundation |
Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
JP2014511687A
(ja)
*
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
DK2691079T3
(da)
|
2011-03-31 |
2020-09-28 |
Ingell Tech Holding B V |
Bionedbrydelige sammensætninger, der er egnet til kontrolleret udløsning
|
|
EP2691078A1
(en)
|
2011-03-31 |
2014-02-05 |
Ingell Technologies Holding B.V. |
Biodegradable compositions suitable for controlled release
|
|
CA2835428A1
(en)
|
2011-05-17 |
2012-11-22 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
|
US20140308363A1
(en)
|
2011-05-31 |
2014-10-16 |
Bind Therapeutics, Inc. |
Drug loaded polymeric nanoparticles and methods of making and using same
|
|
EP3998064A1
(en)
*
|
2011-06-08 |
2022-05-18 |
Translate Bio, Inc. |
Cleavable lipids
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
US8916696B2
(en)
|
2011-06-12 |
2014-12-23 |
City Of Hope |
Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
|
|
EP3854413A1
(en)
*
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
EP3508219A1
(en)
|
2011-07-06 |
2019-07-10 |
GlaxoSmithKline Biologicals S.A. |
Self-replicating rna prime - protein boost vaccines
|
|
EP3456316A1
(en)
*
|
2011-07-06 |
2019-03-20 |
GlaxoSmithKline Biologicals S.A. |
Cationic oil-in-water emulsions
|
|
JP6018197B2
(ja)
|
2011-07-21 |
2016-11-02 |
クローダ インターナショナル パブリック リミティド カンパニー |
分枝状ポリエーテル−ポリアミドブロックコポリマー並びにそれらの製造方法及び使用方法
|
|
HK1199736A1
(en)
|
2011-08-26 |
2015-07-17 |
箭头研究公司 |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
JP2014527071A
(ja)
|
2011-08-31 |
2014-10-09 |
マリンクロッド エルエルシー |
Ｈ−ホスホネートによるナノ粒子ｐｅｇの改変
|
|
US9126966B2
(en)
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
|
TWI570240B
(zh)
|
2011-09-09 |
2017-02-11 |
默沙東公司 |
作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2747761A1
(en)
|
2011-09-22 |
2014-07-02 |
Bind Therapeutics, Inc. |
Methods of treating cancers with therapeutic nanoparticles
|
|
WO2013072929A2
(en)
|
2011-09-23 |
2013-05-23 |
Indian Institute Of Technology |
Nanop article based cosmetic composition
|
|
AU2012322704B2
(en)
*
|
2011-10-11 |
2017-09-07 |
Novartis Ag |
Recombinant self-replicating polycistronic RNA molecules
|
|
US20140348863A1
(en)
|
2011-10-12 |
2014-11-27 |
Alessia Bianchi |
Cmv antigens and uses thereof
|
|
ES2897565T3
(es)
|
2011-10-18 |
2022-03-01 |
Dicerna Pharmaceuticals Inc |
Lípidos catiónicos de amina y uso de los mismos
|
|
MX363734B
(es)
*
|
2011-10-27 |
2019-03-29 |
Massachusetts Inst Technology |
Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco.
|
|
HUE043809T2
(hu)
|
2011-11-04 |
2019-09-30 |
Nitto Denko Corp |
Eljárás lipid-nukleinsav részecskék steril elõállítására
|
|
AU2012335277B2
(en)
*
|
2011-11-11 |
2018-06-14 |
Variation Biotechnologies Inc. |
Compositions and methods for treatment of cytomegalovirus
|
|
WO2013078199A2
(en)
|
2011-11-23 |
2013-05-30 |
Children's Medical Center Corporation |
Methods for enhanced in vivo delivery of synthetic, modified rnas
|
|
EP3988537A1
(en)
|
2011-12-07 |
2022-04-27 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
WO2013090186A1
(en)
|
2011-12-14 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleic acids, and acute care uses thereof
|
|
WO2013130161A1
(en)
|
2011-12-14 |
2013-09-06 |
modeRNA Therapeutics |
Methods of responding to a biothreat
|
|
KR20140102759A
(ko)
*
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
CA2859691A1
(en)
|
2011-12-21 |
2013-06-27 |
Moderna Therapeutics, Inc. |
Methods of increasing the viability or longevity of an organ or organ explant
|
|
US20130195851A1
(en)
|
2011-12-23 |
2013-08-01 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
|
EP3421601B1
(en)
|
2011-12-30 |
2019-12-04 |
Cellscript, Llc |
Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
|
|
RU2598627C2
(ru)
|
2012-01-19 |
2016-09-27 |
Дзе Джонс Хопкинс Юниверсити |
Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013116126A1
(en)
|
2012-02-01 |
2013-08-08 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
EP3312155B1
(en)
|
2012-02-03 |
2020-08-05 |
Rutgers, The State University of New Jersey |
Polymeric biomaterials derived from phenolic monomers and their medical uses
|
|
WO2013120052A1
(en)
|
2012-02-10 |
2013-08-15 |
E. I. Du Pont De Nemours And Company |
Preparation, purification and use of high-x diblock copolymers
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
NZ700075A
(en)
|
2012-02-24 |
2016-05-27 |
Protiva Biotherapeutics Inc |
Trialkyl cationic lipids and methods of use thereof
|
|
US10322089B2
(en)
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
HK1206612A1
(en)
*
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
|
BR112014030677A2
(pt)
*
|
2012-06-08 |
2022-07-19 |
Shire Human Genetic Therapies |
distribuição pulmonar de mrna para células-alvo não-pulmonares
|
|
GB2513768B
(en)
*
|
2012-07-06 |
2015-04-15 |
Novartis Ag |
Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
|
|
ES2719720T3
(es)
|
2012-07-27 |
2019-07-12 |
Hope City |
Una vacuna de MVA para la administración de un complejo de UL128 y para prevenir la infección por CMV
|
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
|
SG11201501623PA
(en)
|
2012-10-30 |
2015-05-28 |
Redvax Gmbh |
Recombinant particle based vaccines against human cytomegalovirus infection
|
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
|
CA2890061A1
(en)
|
2012-12-04 |
2014-06-12 |
Merck Sharp & Dohme Corp. |
Conditional replicating viral vectors
|
|
AU2013355258A1
(en)
|
2012-12-07 |
2015-06-11 |
Alnylam Pharmaceuticals, Inc. |
Improved nucleic acid lipid particle formulations
|
|
WO2014089486A1
(en)
*
|
2012-12-07 |
2014-06-12 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
|
US20150315541A1
(en)
|
2012-12-13 |
2015-11-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
EP2931319B1
(en)
|
2012-12-13 |
2019-08-21 |
ModernaTX, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
HUE055044T2
(hu)
*
|
2013-03-14 |
2021-10-28 |
Translate Bio Inc |
MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
US20160184458A1
(en)
|
2013-03-14 |
2016-06-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
|
US20160017313A1
(en)
|
2013-03-15 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
|
ES3032013T3
(en)
*
|
2013-03-15 |
2025-07-14 |
Translate Bio Inc |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
US11377470B2
(en)
|
2013-03-15 |
2022-07-05 |
Modernatx, Inc. |
Ribonucleic acid purification
|
|
CN105143456A
(zh)
|
2013-03-15 |
2015-12-09 |
不列颠哥伦比亚大学 |
用于转染的脂质纳米粒子和相关方法
|
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
|
EP3578663A1
(en)
|
2013-03-15 |
2019-12-11 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
|
US10246708B2
(en)
|
2013-05-06 |
2019-04-02 |
Alnylam Pharmaceuticals, Inc. |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
|
SG11201510746WA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Respiratory syncytial virus (rsv) vaccine
|
|
EP3888675A1
(en)
|
2013-09-24 |
2021-10-06 |
Duke University |
Compositions, methods and kits for eliciting an immune response
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
AU2014337156A1
(en)
|
2013-10-18 |
2016-05-12 |
Modernatx, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
WO2015061467A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Lipid formulations for delivery of messenger rna
|
|
DK3077519T3
(en)
|
2013-12-03 |
2021-06-14 |
Hookipa Biotech Gmbh |
Cmv-vacciner
|
|
WO2015089340A1
(en)
|
2013-12-11 |
2015-06-18 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines
|
|
ES2908827T3
(es)
|
2013-12-19 |
2022-05-04 |
Novartis Ag |
Lípidos y composiciones lipídicas para el suministro de agentes activos
|
|
EP3623361B1
(en)
|
2013-12-19 |
2021-08-18 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
WO2015110659A1
(en)
|
2014-01-27 |
2015-07-30 |
Bionor Immuno As |
Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
|
|
ES2774552T3
(es)
|
2014-03-24 |
2020-07-21 |
Translate Bio Inc |
Terapia de ARNm para el tratamiento de enfermedades oculares
|
|
WO2015165480A1
(en)
|
2014-04-30 |
2015-11-05 |
Institute For Research In Biomedicine |
Human cytomegalovirus vaccine compositions and method of producing the same
|
|
WO2015161926A1
(en)
|
2014-04-23 |
2015-10-29 |
Institute For Research In Biomedicine |
Human cytomegalovirus vaccine compositions and method of producing the same
|
|
RU2021109685A
(ru)
|
2014-04-23 |
2021-04-13 |
МОДЕРНАТиЭкс, ИНК. |
Вакцины на основе нуклеиновых кислот
|
|
WO2015170287A1
(en)
|
2014-05-08 |
2015-11-12 |
Redvax Gmbh |
Means and methods for treating cmv
|
|
WO2015181142A1
(en)
|
2014-05-27 |
2015-12-03 |
Glaxosmithkline Biologicals S.A. |
Cytomegalovirus complexes and uses thereof
|
|
US10286086B2
(en)
|
2014-06-19 |
2019-05-14 |
Modernatx, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
IL289934B2
(en)
|
2014-06-25 |
2023-04-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CN106456547B
(zh)
|
2014-07-02 |
2021-11-12 |
川斯勒佰尔公司 |
信使rna的包封
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
JP2017523777A
(ja)
|
2014-07-17 |
2017-08-24 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
ポリヌクレオチドの末端修飾
|
|
ES2969956T3
(es)
|
2014-09-05 |
2024-05-23 |
Novartis Ag |
Lípidos y composiciones lipídicas para el suministro de agentes activos
|
|
EP3015475A1
(en)
|
2014-10-31 |
2016-05-04 |
Novartis AG |
Mammalian cells expressing cytomegalovirus antigens
|
|
EP3031822A1
(en)
|
2014-12-08 |
2016-06-15 |
Novartis AG |
Cytomegalovirus antigens
|
|
US20180000953A1
(en)
|
2015-01-21 |
2018-01-04 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
EP3048114A1
(en)
|
2015-01-22 |
2016-07-27 |
Novartis AG |
Cytomegalovirus antigens and uses thereof
|
|
EP3047856A1
(en)
|
2015-01-23 |
2016-07-27 |
Novartis AG |
Cmv antigens and uses thereof
|
|
KR20170136512A
(ko)
|
2015-02-10 |
2017-12-11 |
오레곤 헬스 앤드 사이언스 유니버시티 |
넌-캐노니컬 cd8+ t 세포 반응 생성에 유용한 방법 및 조성물
|
|
WO2016133881A1
(en)
|
2015-02-16 |
2016-08-25 |
Kamil Jeremy P |
Method of altering expression of alternative viral glycoprotein complexes
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
AU2016264027A1
(en)
|
2015-05-15 |
2017-08-31 |
Curevac Ag |
Prime-boost regimens involving administration of at least one mRNA construct
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
EP3310384A1
(en)
|
2015-06-17 |
2018-04-25 |
CureVac AG |
Vaccine composition
|
|
CN114085198A
(zh)
|
2015-06-29 |
2022-02-25 |
爱康泰生治疗公司 |
用于递送核酸的脂质和脂质纳米颗粒制剂
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
EP4218805A1
(en)
|
2015-07-21 |
2023-08-02 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
EP3328394A4
(en)
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
CONCATEMEE peptide epitope RNAs
|
|
US20190008887A1
(en)
|
2015-07-30 |
2019-01-10 |
ModernaTX Inc. |
Multimeric mrna
|
|
WO2017031241A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
EP3350157B1
(en)
|
2015-09-17 |
2022-01-05 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
JP7687767B2
(ja)
|
2015-10-22 |
2025-06-03 |
モデルナティエックス インコーポレイテッド |
呼吸器合胞体ウイルスワクチン
|
|
JP6925688B2
(ja)
|
2015-10-22 |
2021-08-25 |
モデルナティーエックス， インコーポレイテッド |
水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
CA3002819A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
CA3003103A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
MA47016A
(fr)
|
2015-10-22 |
2018-08-29 |
Modernatx Inc |
Vaccins contre les virus respiratoires
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
BR112018008090A2
(pt)
|
2015-10-22 |
2018-11-13 |
Modernatx Inc |
vacina de vírus do herpes simplex.
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
ES2924407T3
(es)
|
2015-12-10 |
2022-10-06 |
Modernatx Inc |
Composiciones y procedimientos para el suministro de agentes terapéuticos
|
|
WO2017106799A1
(en)
|
2015-12-17 |
2017-06-22 |
Modernatx, Inc. |
POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
US11078247B2
(en)
|
2016-05-04 |
2021-08-03 |
Curevac Ag |
RNA encoding a therapeutic protein
|
|
EP3458108A4
(en)
|
2016-05-18 |
2020-04-22 |
ModernaTX, Inc. |
POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
|
|
CA3024507A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
|
|
WO2017201317A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
EP3458106A4
(en)
|
2016-05-18 |
2020-03-18 |
Modernatx, Inc. |
POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
|
|
ES2973443T3
(es)
|
2016-05-18 |
2024-06-20 |
Modernatx Inc |
Polinucleótidos que codifican galactosa-1-fosfato uridililtransferasa para el tratamiento de galactosemia de tipo 1
|
|
EP3458081A1
(en)
|
2016-05-18 |
2019-03-27 |
Modernatx, Inc. |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
|
MA45037A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polythérapie à base d'arnm pour le traitement du cancer
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
KR102533456B1
(ko)
|
2016-05-18 |
2023-05-17 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
US20200085916A1
(en)
|
2016-05-18 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
|
|
WO2017208191A1
(en)
|
2016-06-02 |
2017-12-07 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
|
US20200069599A1
(en)
|
2016-06-14 |
2020-03-05 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CA3036831A1
(en)
|
2016-09-14 |
2018-03-22 |
Modernatx, Inc. |
High purity rna compositions and methods for preparation thereof
|
|
CA3041307A1
(en)
|
2016-10-21 |
2018-04-26 |
Giuseppe Ciaramella |
Human cytomegalovirus vaccine
|
|
MA46643A
(fr)
|
2016-10-26 |
2019-09-04 |
Modernatx Inc |
Méthodes et compositions pour le mappage d'arn
|
|
IL317855A
(en)
|
2016-10-26 |
2025-02-01 |
Acuitas Therapeutics Inc |
mRNA vaccines with lipid nanoparticles
|
|
SG11201903674YA
(en)
|
2016-10-26 |
2019-05-30 |
Modernatx Inc |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US10925958B2
(en)
|
2016-11-11 |
2021-02-23 |
Modernatx, Inc. |
Influenza vaccine
|
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
|
EP3555289A1
(en)
|
2016-12-13 |
2019-10-23 |
ModernaTX, Inc. |
Rna affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
WO2018144775A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
EP3577221A4
(en)
|
2017-02-01 |
2020-12-23 |
ModernaTX, Inc. |
Polynucleotide secondary structure
|
|
AU2017397458B2
(en)
|
2017-02-01 |
2025-07-10 |
Modernatx, Inc. |
RNA cancer vaccines
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
WO2018157009A1
(en)
|
2017-02-24 |
2018-08-30 |
Modernatx, Inc. |
Nucleic acid-based therapy of muscular dystrophies
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
FI3596041T3
(fi)
|
2017-03-15 |
2023-01-31 |
|
Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
WO2018175783A1
(en)
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
EP3607074A4
(en)
|
2017-04-05 |
2021-07-07 |
Modernatx, Inc. |
REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
|
|
US20200054737A1
(en)
|
2017-04-26 |
2020-02-20 |
Modema TX, Inc. |
Herpes simplex virus vaccine
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
MA49914A
(fr)
|
2017-08-18 |
2021-04-21 |
Modernatx Inc |
Procédés analytiques par hplc
|
|
ES2983060T3
(es)
|
2017-08-18 |
2024-10-21 |
Modernatx Inc |
Variantes de ARN polimerasa
|
|
US20200254086A1
(en)
|
2017-08-18 |
2020-08-13 |
Moderna TX, Inc. |
Efficacious mrna vaccines
|
|
EP3668979A4
(en)
|
2017-08-18 |
2021-06-02 |
Modernatx, Inc. |
METHOD OF HPLC ANALYSIS
|
|
MA50253A
(fr)
|
2017-09-14 |
2020-07-22 |
Modernatx Inc |
Vaccins à arn contre le virus zika
|
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
|
CA3083102A1
(en)
|
2017-11-21 |
2019-05-31 |
Modernatx, Inc. |
Epstein-barr virus vaccines
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
EP3813848A4
(en)
|
2018-06-27 |
2022-07-20 |
ModernaTX, Inc. |
EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE
|
|
AU2019338557A1
(en)
|
2018-09-13 |
2021-03-25 |
Modernatx, Inc. |
Modified mRNA for the treatment of progressive familial intrahepatic cholestasis disorders
|
|
EP4509118A3
(en)
|
2018-09-19 |
2025-05-14 |
ModernaTX, Inc. |
High-purity peg lipids and uses thereof
|
|
WO2020061284A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020097291A1
(en)
|
2018-11-07 |
2020-05-14 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
CA3130888A1
(en)
|
2019-02-20 |
2020-08-27 |
Modernatx, Inc. |
Rna polymerase variants for co-transcriptional capping
|
|
CN113874502A
(zh)
|
2019-03-11 |
2021-12-31 |
摩登纳特斯有限公司 |
补料分批体外转录方法
|
|
US12070495B2
(en)
|
2019-03-15 |
2024-08-27 |
Modernatx, Inc. |
HIV RNA vaccines
|
|
CA3142352A1
(en)
|
2019-05-31 |
2020-12-03 |
Modernatx, Inc. |
Expanded t cell assay
|
|
JP2022544416A
(ja)
|
2019-08-14 |
2022-10-18 |
モデルナティエックス インコーポレイテッド |
ｉｎ ｖｉｔｒｏ転写の下流生成物を精製するプロセス
|
|
JP2022547313A
(ja)
|
2019-09-11 |
2022-11-11 |
モデルナティエックス インコーポレイテッド |
ヒトサイトメガロウイルスワクチン
|
|
JP2022548957A
(ja)
|
2019-09-19 |
2022-11-22 |
モデルナティエックス インコーポレイテッド |
キャップガイド及びｒｎａマッピングのためのその使用方法
|
|
WO2021142306A1
(en)
|
2020-01-10 |
2021-07-15 |
Modernatx, Inc. |
Variational autoencoder for biological sequence generation
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
JP2023513073A
(ja)
|
2020-01-30 |
2023-03-30 |
モデルナティエックス インコーポレイテッド |
呼吸器系ウイルス免疫化組成物
|
|
KR20220140528A
(ko)
|
2020-02-07 |
2022-10-18 |
모더나티엑스, 인크. |
Sars-cov-2 mrna 도메인 백신
|
|
WO2021211343A1
(en)
|
2020-04-13 |
2021-10-21 |
Modernatx, Inc. |
Zika virus mrna vaccines
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
US20230142529A1
(en)
|
2020-05-15 |
2023-05-11 |
Modernatx, Inc. |
Rna formulations for high volume distribution
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
WO2021237084A1
(en)
|
2020-05-21 |
2021-11-25 |
Modernatx, Inc. |
Methylene blue stabilized mrna compositions
|
|
CA3185855A1
(en)
|
2020-06-05 |
2021-12-09 |
Modernatx, Inc. |
Bacterial strains for dna production
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20230355743A1
(en)
|
2020-09-25 |
2023-11-09 |
Modernatx, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|